Современные аспекты лечения BRCA-ассоциированного рака яичников


А.А. Румянцев

Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина; Москва, Россия
Рак яичников (РЯ) по-прежнему остается ведущий причиной смертности от онкогинекологических заболеваний. В данной статье представлен актуальный обзор данных о частоте встречаемости BRCA-ассоциированного РЯ. Рассмотрены различные аспекты лечения больных этим заболеванием, в т.ч. особенности проведения химиотерапии при BRCA-ассоциированном РЯ, а также роль и перспективы развития новых методов лечения, включая таргетную терапию и иммунотерапию. Информация о наличии мутации в генах BRCA1/2 может оказать значимое влияние на лечение больных поздними стадиями РЯ на всех этапах лечения пациенток. Проведение дальнейших исследований в этой области, в т.ч. с использованием современных таргетных и иммунотерапевтических агентов, должно способствовать улучшению результатов лечения больных.

Литература


1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные заболевания в России в 2014 году (заболеваемость и смертность). М., 2018. 250 с.

2. Howlader N., Noone A.M., Krapcho M.,et al. SEER Cancer Statistics Review, 1975–2012, based on November 2014 SEER data submission, posted to the SEER web site. April 2015.

3. Stratton J.F., Pharoah P.D.P, Smith S.K., et al. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynecol. 1998;105:493.

4. Kuchenbaecker K.B., Hopper J.L., Barnes D.R., et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–16.

5. Soegaard M., Kjaer S.K., Cox M., et al. BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark. Clinical Cancer Research. Clin Cancer Res. 2008;14(12):3761–67.

6. Satagopan J.M., Boyd J., Kauff N.D., et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002;8(12):3776–81.

7. Alsop K., et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 2012;30:2654–63.

8. Møller P., Hagen A.I., Apold J., et al. Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers. Eur J Cancer. 2007;43(11):1713–17.

9. George A., Kaye S., Banerjee S., et al. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14(5):284–96.

10. Pennington K.P., et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 2014;20:764–75.

11. Ledermann J., Harter P., Gourley C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.

12. Yun M.H., Hiom K. Understanding the functions of BRCA1 in the DNA-damage response. Biochem Soc Trans. 2009;37(Pt 3):597–604.

13. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26(22):3785–90.

14. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21.

15. Konstantinopoulos P.A., Ceccaldi R., Shapiro G.I., et al. Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov. 2015;5(11):1137–54.

16. Ledermann J., Harter P., Gourley C., et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61.

17. Государственный Реестр Лекарственных Средств. Инструкция по применению лекарственного препарата для медицинского применения препарата Линпарза от 11.07.2016.

18. Kaufman B., Shapira-Frommer R., Schmutzler R.K. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50.

19. FDA Approves Olaparib (Lynparza) for BRCA Ovarian Cancer. Medscape. Dec 19, 2014. URL: http://www.medscape.com/viewarticle/836955.

20. Drugs@FDA. Full Prescribing Information for Olaparib (Lynparza). URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208558s001lbl.pdf.

21. European Medicines Agency. Lynparza Product Information. URL: https://www.ema.europa.eu/medicines/human/EPAR/lynparza#product-information-section.

22. European Medicines Agency. Zejula Product Information. URL: https://www.ema.europa.eu/documents/product-information/zejula-epar-product-information_en.pdf.

23. Ison G., Howie L., Amiri-Kordestani L., et al. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Clin Cancer Res. 2018;24(17):4066–71.

24. European Medicines Agency. Rubraca Product Information. URL: https://www.ema.europa.eu/documents/product-information/rubraca-epar-product-information_en.pdf.

25. Drugs@FDA. Full Prescribing Information for Rucaparib (Rubraca). URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209115s003lbl.pdf.

26. Coleman R.L., Oza A.M., Lorusso D., et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:1949–61.

27. Mirza M.R., Monk B.J., Herrstedt J., et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375:2154–64.

28. Pujade-Lauraine E., Ledermann J.A., Selle F., et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274–84.

29. NCCN Clinical Practice Guidelines. Antiemesis. Version 3.2018. June 11, 2018. URL: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.

30. Gunderson C.C., Matulonis U., Moore K.N. Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecol Oncol. 2018;148(3):591–600.

31. Friedlander M., Gebski V., Gibbs E., et al. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial. Lancet Oncol. 2018;19(8):1126–34.

32. Oza A.M. Matulonis U.A., Malander S., et al. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomized controlled trial. Lancet Oncol. 2018;19(8):1117–25.

33. Ledermann J.A., Harter P., Gourley C., et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579–89.

34. Matulonis U.A., Harter P., Gourley C. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016;122(12):1844–52.

35. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43.

36. Howell S.B., Pfeifle C.L., Wung W.E. et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97(6):845–51.

37. Fujiwara K., Nagao S., Aotani E., et al. Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer. Expert Opin Pharmacother. 2013;14(13):1797–806.

38. Lesnock J.L., Darcy K.M., Tian C., et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer. 2013;108(6):1231–37.

39. Тюляндин С.А., Коломиец Л.А., Морхов К.Ю. и др. Практические рекомендации по лекарственному лечению рака яичников, первичного рака брюшины и рака маточных труб. Злокачественные опухоли: Практические рекомендации RUSSCO №3s2, 2017 (том 7). С. 135–45.

40. NCCN Clinical Practice Guidelines. Ovarian cancer. Version 4.2017. Доступно по адресу: https://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf.

41. Tan D.S., Rothermundt C., Thomas K., et al. «BRCAness» syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26(34):5530–36.

42. Wang W., Zou W., Liu J.R., et al. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy. Gynecol Oncol. 2018;151(1):1–3.

43. Zhang L., Conejo-Garcia J.R., Katsaros D., et al. Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. N Engl J Med. 2003;348(3):203–13.

44. Hamanishi J., Mandai M., Ikeda T., et al. Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. J Clin Oncol. 2015;33(34):4015–22.

45. Strickland K.C., Howitt B.E., Shukla S.A., et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(12):13587–98.

46. Matsuo K., Spragg S.E., Ciccone M.A., et al. Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series. Gynecol Oncol Rep. 2018;25:98–101.

47. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.


Об авторах / Для корреспонденции


Автор для связи: А.А. Румянцев, НМИЦ онкологии им. Н.Н. Блохина, Москва, Россия; e-mail: alexeymma@gmail.com
Адрес: 115478, Россия, Москва, Каширское шоссе, 24


Похожие статьи


Бионика Медиа